Calvert Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Calvert Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-10,996	Closed	-$911K	–	94
2016 Q4	$911K	Sell	10,996 -144	-1%	-$12.4K	0.03%	397
2016 Q3	$1.03M	Buy	11,140 +1,406	+14%	+$132K	0.04%	378
2016 Q2	$757K	Buy	9,734 +476	+5%	+$40.5K	0.03%	413
2016 Q1	$764K	Buy	9,258 +2,693	+41%	+$219K	0.03%	375
2015 Q4	$688K	Buy	6,565 +1,256	+24%	+$131K	0.03%	374
2015 Q3	$559K	Buy	5,309 +222	+4%	+$29.7K	0.03%	332
2015 Q2	$696K	Buy	+5,087	New	+$630K	0.03%	304

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Calvert Investment Management's BMRN Position: Q1 2017 in Review

Calvert Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2017, closing a stake of 10,996 shares — an estimated $911K sold.

Calvert Investment Management first reported a position in BMRN in Q2 2015 and held it in 7 quarters. The position peaked at $1.03M in Q3 2016. 418 funds tracked by Wall St. Rank hold BMRN as of Q1 2017.

Calvert Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Calvert Investment Management sold 10,996 BioMarin Pharmaceuticals shares in Q1 2017, an estimated $911K.
Calvert Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 7 quarters.
Calvert Investment Management's BioMarin Pharmaceuticals position peaked at $1.03M in Q3 2016.
418 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2017.

Based on Calvert Investment Management's 13F filing for Q1 2017.